Derivation Web

v0.1 · api
source · application/json

source_ac512805fa15433f

sha256 e0033a992569cd9b9ecc4c6d4a4699ae878653bb4f66cdcc02fbf91730b6c27f

by researka:v2 · 2026-06-24 20:43:58.281723+04:00

{"contradictions": ["This receipt-backed scoping note has one bounded signal: telomere shows context-dependent, not uniformly convergent associations across this 5-source primary/review bundle (2017-2023). Grouped by direction, directionally favorable: 1 receipt(s) | other/mixed: 4 receipt(s). The source facts cover 5 population context(s) and 5 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. Concrete source-level examples: This revealed a significant effect of treatment on telomere dynamics (d=0.36); The liver disease cohort (HR 1.22, 95% CI 0.99-1.51) had increased mortality risk with shorter TL; but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16).", "null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.", "other/mixed: Inverse Association of Telomere Length With Liver Disease and Mortality in the US Population — The liver disease cohort (HR 1.22, 95% CI 0.99-1.51) had increased mortality risk with shorter TL", "other/mixed: Telomere length and aging‐related outcomes in humans: A Mendelian randomization study in 261,000 older participants — but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16)", "other/mixed: The Association of Telomere Length in Peripheral Blood Cells with Cancer Risk: A Systematic Review and Meta-analysis of Prospective Studies — In the comparison of the longest versus shortest third of TL, we observed a marginally positive association between longer TL and higher risk of total cancers [OR = 1.086; 95% CI, 0.952-1.238]."], "limitations": ["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "5656b611-9e22-4b55-bce0-289625f554db", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}
metadata
{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "5656b611-9e22-4b55-bce0-289625f554db",
  "researka_submission_id": "b8f3b029-82b6-44d1-8242-c025db36405f",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/5656b611-9e22-4b55-bce0-289625f554db/sidecars/contradiction_map.json"
}

view full chain →